NCT02220855View on ClinicalTrials.gov

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

PHASE2CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

March 27, 2017

Study Completion Date

March 9, 2021

Conditions

Thymoma

Interventions

DRUG

BKM120

Trial Locations (1)

46202

Indiana University Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Patrick Joseph Loehrer Sr.

OTHER